2016 Hematological Malignancies

819 / 1835

• Registrational phase 2 study conducted in Europe and North America
CheckMate 205: Study Design, Cohort B
Engert et al 2015
Primary endpoint
• ORR assessed by IRRCa
Secondary and other endpoints
• IRRC-assessed DOR for complete and
partial remission
• Investigator-assessed ORR and DOR
• IRRC-assessed PFS
• OS
• Safety
• QoL
• Biomarkers
a
Minimum follow-up:
6 months
Single-arm
Nivolumab 3 mg/kg
(every 2 weeks)
Treatment until disease
progression or unacceptable
toxicity
Prior ASCT
Brentuximab vedotin
Relapsed/refractory cHL
Inclusion criteria
• Patients could elect to discontinue nivolumab and proceed to allogeneic hematopoietic
stem cell transplantation